

PROPOSED IRA

[Proposed Interim Revision Announcements](#)

USP MONOGRAPHS

[Insulin \(1-JAN-2019\)](#)

[Insulin Injection \(1-JAN-2019\)](#)

[Insulin Aspart Injection \(1-JAN-2019\)](#)

[Human Insulin Isophane Suspension and Human Insulin Injection \(1-JAN-2019\)](#)

[Isophane Insulin Suspension \(1-JAN-2019\)](#)

[Isophane Insulin Human Suspension \(1-JAN-2019\)](#)

[Insulin Lispro \(1-JAN-2019\)](#)

[Insulin Lispro Injection \(1-JAN-2019\)](#)

[Insulin Zinc Suspension \(1-JAN-2019\)](#)

IN-PROCESS REVISION

[In-Process Revision](#)

GENERAL CHAPTERS

[<203> HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY PROCEDURE FOR IDENTIFICATION OF ARTICLES OF BOTANICAL ORIGIN \(USP42-NF37 2S\)](#)

[<591> ZINC DETERMINATION \(USP42-NF37 2S\)](#)

[<607> PHARMACEUTICAL FOAMS-PRODUCT QUALITY TESTS \[NEW\] \(USP42-NF37 2S\)](#)

[<659> PACKAGING AND STORAGE REQUIREMENTS \(USP42-NF37 2S\)](#)

[<861> SUTURES-DIAMETER \(USP42-NF37 2S\)](#)

[<871> SUTURES-NEEDLE ATTACHMENT \(USP42-NF37 2S\)](#)

[<881> TENSILE STRENGTH \(USP42-NF37 2S\)](#)

[<1079> GOOD STORAGE AND DISTRIBUTION PRACTICES FOR DRUG PRODUCTS \(USP42-NF37 2S\)](#)

[<1085> GUIDELINES ON THE ENDOTOXINS TEST \[NEW\] \(USP42-NF37 2S\)](#)

[<1430> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-GENERAL \[NEW\] \(USP42-NF37 2S\)](#)

[<1430.1> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-STATIC LIGHT SCATTERING \[NEW\] \(USP42-NF37 2S\)](#)

[<1430.2> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-LIGHT DIFFRACTION MEASUREMENTS OF PARTICLE SIZE \[NEW\] \(USP42-NF37 2S\)](#)

[<1430.3> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-DYNAMIC LIGHT SCATTERING \[NEW\] \(USP42-NF37 2S\)](#)

[<1430.4> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-ELECTROPHORETIC LIGHT SCATTERING \(DETERMINATION OF ZETA POTENTIAL\) \[NEW\] \(USP42-NF37 2S\)](#)

[<1430.5> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA-SMALL-ANGLE X-RAY SCATTERING AND SMALL-ANGLE NEUTRON SCATTERING \[NEW\] \(USP42-NF37 2S\)](#)

[<1602> SPACERS AND VALVED HOLDING CHAMBERS USED WITH INHALATION](#)

[AEROSOLS-CHARACTERIZATION TESTS \(USP42-NF37 2S\)](#)
[<2091> WEIGHT VARIATION OF DIETARY SUPPLEMENTS \(USP42-NF37 2S\)](#)

REAGENTS, INDICATORS, AND SOLUTIONS

Reagent Specifications

[Aqua Regia \[NEW\] \(USP42-NF37 2S\)](#)
[Triphenylphosphine Oxide \[NEW\] \(USP42-NF37 2S\)](#)
[Water, Ammonia-Free \(USP42-NF37 2S\)](#)

Test Solutions

[25% Tetrabutylammonium Hydroxide TS \[NEW\] \(USP42-NF37 2S\)](#)

REFERENCE TABLES

Container Specifications

[Container Specifications \[NEW\] \(USP42-NF37 2S\)](#)

Description and Solubility

[Description and Relative Solubility of USP and NF Articles \(USP42-NF37 2S\)](#)
[Description and Solubility - N](#)
[Description and Solubility - P](#)
[Description and Solubility - R](#)
[Description and Solubility - S](#)

USP MONOGRAPHS

[Acetaminophen Oral Solution \(USP42-NF37 2S\)](#)
[Albuterol Tablets \(USP42-NF37 2S\)](#)
[Aminobenzoate Potassium Tablets \(USP42-NF37 2S\)](#)
[Aminobenzoate Sodium \(USP42-NF37 2S\)](#)
[Amitriptyline Hydrochloride \(USP42-NF37 2S\)](#)
[Bimatoprost \[NEW\] \(USP42-NF37 2S\)](#)
[Bimatoprost Ophthalmic Solution \[NEW\] \(USP42-NF37 2S\)](#)
[Brimonidine Tartrate Ophthalmic Solution \[NEW\] \(USP42-NF37 2S\)](#)
[Bupropion Hydrochloride \(USP42-NF37 2S\)](#)
[Bupropion Hydrochloride Tablets \(USP42-NF37 2S\)](#)
[Bupropion Hydrochloride Extended-Release Tablets \(USP42-NF37 2S\)](#)
[Carbidopa and Levodopa Tablets \(USP42-NF37 2S\)](#)
[Clarithromycin Extended-Release Tablets \(USP42-NF37 2S\)](#)
[Clindamycin Phosphate Vaginal Cream \(USP42-NF37 2S\)](#)
[Clindamycin Phosphate Gel \(USP42-NF37 2S\)](#)
[Clonidine Hydrochloride \(USP42-NF37 2S\)](#)
[Clonidine Hydrochloride Injection \[NEW\] \(USP42-NF37 2S\)](#)
[Doxycycline Compounded Oral Suspension, Veterinary \(USP42-NF37 2S\)](#)
[Edetate Disodium Compounded Ophthalmic Solution \[NEW\] \(USP42-NF37 2S\)](#)
[Erythromycin \(USP42-NF37 2S\)](#)
[Erythromycin Ethylsuccinate \(USP42-NF37 2S\)](#)

[Erythromycin Stearate \(USP42-NF37 2S\)](#)
[Glycopyrrolate \(USP42-NF37 2S\)](#)
[Indomethacin Extended-Release Capsules \(USP42-NF37 2S\)](#)
[Insulin Human \(USP42-NF37 2S\)](#)
[Iodinated I 131 Albumin Aggregated Injection \(USP42-NF37 2S\)](#)
[Krypton Kr 81m \(USP42-NF37 2S\)](#)
[Levobunolol Hydrochloride Ophthalmic Solution \(USP42-NF37 2S\)](#)
[Lidocaine Hydrochloride Oral Topical Solution \(USP42-NF37 2S\)](#)
[Lidocaine Hydrochloride Topical Solution \(USP42-NF37 2S\)](#)
[Magaldrate Oral Suspension \(USP42-NF37 2S\)](#)
[Magaldrate Tablets \(USP42-NF37 2S\)](#)
[Magnesia Tablets \(USP42-NF37 2S\)](#)
[Mazindol \(USP42-NF37 2S\)](#)
[Mazindol Tablets \(USP42-NF37 2S\)](#)
[Menadiol Sodium Diphosphate \(USP42-NF37 2S\)](#)
[Menadiol Sodium Diphosphate Injection \(USP42-NF37 2S\)](#)
[Menadiol Sodium Diphosphate Tablets \(USP42-NF37 2S\)](#)
[Menadione Injection \(USP42-NF37 2S\)](#)
[Meropenem \(USP42-NF37 2S\)](#)
[Meropenem for Injection \(USP42-NF37 2S\)](#)
[Methylbenzethonium Chloride Ointment \(USP42-NF37 2S\)](#)
[Methylbenzethonium Chloride Topical Powder \(USP42-NF37 2S\)](#)
[Methylprednisolone Sodium Succinate for Injection \(USP42-NF37 2S\)](#)
[Monobenzone \(USP42-NF37 2S\)](#)
[Monobenzone Cream \(USP42-NF37 2S\)](#)
[Moricizine Hydrochloride \(USP42-NF37 2S\)](#)
[Nicardipine Hydrochloride Injection \(USP42-NF37 2S\)](#)
[Nitazoxanide \[NEW\] \(USP42-NF37 2S\)](#)
[Omeprazole and Sodium Bicarbonate Capsules \[NEW\] \(USP42-NF37 2S\)](#)
[Oxprenolol Hydrochloride Tablets \(USP42-NF37 2S\)](#)
[Oxycodone Hydrochloride Oral Solution \(USP42-NF37 2S\)](#)
[Piperacillin Sodium \(USP42-NF37 2S\)](#)
[Pregabalin \(USP42-NF37 2S\)](#)
[Pseudoephedrine Hydrochloride \(USP42-NF37 2S\)](#)
[Pseudoephedrine Hydrochloride Extended-Release Tablets \(USP42-NF37 2S\)](#)
[Quinapril Tablets \(USP42-NF37 2S\)](#)
[Rifabutin \(USP42-NF37 2S\)](#)
[Rifabutin Capsules \(USP42-NF37 2S\)](#)
[Ropivacaine Hydrochloride \(USP42-NF37 2S\)](#)
[Rufinamide Tablets \(USP42-NF37 2S\)](#)
[Sodium Fluoride Gel \(USP42-NF37 2S\)](#)
[Absorbable Surgical Suture \(USP42-NF37 2S\)](#)
[Nonabsorbable Surgical Suture \(USP42-NF37 2S\)](#)
[Tetracycline Hydrochloride Capsules \(USP42-NF37 2S\)](#)
[Tizanidine Capsules \[NEW\] \(USP42-NF37 2S\)](#)
[Triamterene and Hydrochlorothiazide Tablets \(USP42-NF37 2S\)](#)

[Trifluridine \(USP42-NF37 2S\)](#)

[Valproate Sodium Injection \(USP42-NF37 2S\)](#)

DIETARY SUPPLEMENT MONOGRAPHS

[Ascorbic Acid Chewable Gels \(USP42-NF37 2S\)](#)

[Cholecalciferol Chewable Gels \(USP42-NF37 2S\)](#)

[Menaquinone-7 \(USP42-NF37 2S\)](#)

[Menaquinone-7 Preparation \(USP42-NF37 2S\)](#)

[Pyroloquinoline Quinone Disodium \[NEW\] \(USP42-NF37 2S\)](#)

EXCIPIENTS

Excipients (USP and NF), Listed By Category (USP42-NF37 2S)

[Briefing](#)

[Introduction](#)

[Emollient](#)

[Solvent](#)

[Vehicle](#)

NF MONOGRAPHS

[Aluminum Monostearate \(USP42-NF37 2S\)](#)

[Hexylene Glycol \(USP42-NF37 2S\)](#)

[Polypropylene Glycol 11 Stearyl Ether \[NEW\] \(USP42-NF37 2S\)](#)

STAGE 4 HARMONIZATION

[Stage 2 Harmonization](#)

STIMULI TO THE REVISION PROCESS

[STIMULI TO THE REVISION PROCESS](#)

[Modernization of Color Measurement Methods in the USP-NF](#)

[The Application of Abbreviated Impactor Measurement and Efficient Data Analysis in the](#)

[Lifecycle of an Orally-Inhaled Product: A Roadmap](#)

[The Use of Mean Kinetic Temperature to Aid Evaluation of Temperature Excursions: Proper and](#)

[Improper Application](#)